Metabolon has quickly become a leader in the application of metabolomics to design novel therapies. Located in Research Triangle Park, North Carolina, Metabolon is based in a biotechnology epicenter. We are leaders in the use of metabolomic technology, initially focusing on drug development and treatment for ALS. In collaboration with Massachusetts General Hospital, our program has identified biomarkers for the disease and for the action of Rilutek®, an Aventis drug for the treatment of ALS.